Prevention

Find the latest research associated with preventative efforts to reduce the disease burden of COVID-19.

1. Virus Inactivation
2. Passive and Induced Immunity
3. Vaccine Design and Development

August 2020

• Articles to be added shortly

July 2020

• *NEW Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.
• Far-UVC light (222 nm) efficiently and safely inactivates airborne human coronaviruses.

June 2020

• Airborne SARS-CoV-2 is Rapidly Inactivated by Simulated Sunlight.
• Evaluation of Chemical Protocols for Inactivating SARS-CoV-2 Infectious Samples.
• Influence of Different Inactivation Methods on Severe Acute Respiratory Syndrome Coronavirus 2 RNA Copy Number​.

May 2020

• Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody.
• Identification of Human Single-Domain Antibodies against SARS-CoV-2.
• Effective Heat Inactivation of SARS-CoV-2.
• Effectiveness of Ultraviolet-C Light and a High-Level Disinfection Cabinet for Decontamination of N95 Respirators.

April 2020

• Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1.

 

back to top

August 2020

• Articles to be added shortly

July 2020

• *NEW Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion.

June 2020

• Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients.

May 2020

• Can post-exposure prophylaxis for COVID-19 be considered as one of outbreak response strategies in long-term care hospitals?

April 2020

• SARS-CoV-2: Is it the newest spark in the TORCH?

back to top

August 2020

• *NEW Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections.
• *NEW Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate.
• *NEW Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

July 2020

• An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates.
• A Versatile Platform to Incorporate Viral Trimeric Antigens into Self-Assembling Nanoparticle Immunogens.
• Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis.
• Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine.
• Current status of COVID-19 (pre)clinical vaccine development.
• An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
• A Targeted Vaccine against COVID-19: S1-Fc Vaccine Targeting the Antigen-Presenting Cell Compartment Elicits Protection against SARS-CoV-2 Infection.
• SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.
• Vaccination against coronaviruses in domestic animals.

June 2020

• COVIDep: a web-based platform for real-time reporting of vaccine target recommendations for SARS-CoV-2.
• Nanotechnology for COVID-19: Therapeutics and Vaccine Research.
• Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?
• COVID-19 Vaccine Development: Time to Consider SARS-CoV-2 Challenge Studies?
• Immunoinformatics and Structural Analysis for Identification of Immunodominant Epitopes in SARS-CoV-2 as Potential Vaccine Targets.
• Vaccination strategies to combat novel corona virus SARS-CoV-2.
• Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.
• Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.

May 2020

• Adverse Consequences of Rushing a SARS-CoV-2 Vaccine: Implications for Public Trust.
• Immunogenicity of a DNA vaccine candidate for COVID-19.
• BCG-induced trained immunity: can it offer protection against COVID-19?
• COVID-19 Clinical Trial Oversight at a Major Academic Medical Center: Approach of the Michigan Medicine COVID-19 Clinical Trial Committees.

April 2020

• The race for coronavirus vaccines: a graphical guide.
• Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine induces equivalent preclinical antibody titers and viral neutralization to recovered COVID-19 patients.
• A single dose of ChAdOx1 MERS provides broad protective immunity against a variety of MERS-CoV strains.
• Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization.
• A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.
• Vaccines For COVID-19: Perspectives, Prospects, And Challenges Based On Candidate Sars, Mers, And Animal Coronavirus Vaccines.
• The SARS-CoV-2 Vaccine Pipeline: An Overview.
• SARS-CoV-2 Vaccines: Status Report.

back to top